Alzai Health (FRA:H2F) Research & Development: €0.58 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health Research & Development?

Alzai Health FRA:H2F -1.62% 9 Research & Development is €0.58 Mil as of Jan. 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alzai Health's Research & Development for the three months ended in Jan. 2026 was €0.33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was €0.58 Mil.

Alzai Health  (FRA:H2F) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alzai Health Research & Development Related Terms

Alzai Health Research & Development Historical Data

* Premium members only.

The historical data trend for Alzai Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Research & Development Chart

Alzai Health Annual Data
Trend Apr25
Research & Development
0.00

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
Research & Development 0.04 0.05 0.10 0.10 0.33
FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.58 Mil mean?
Alzai Health (FRA:H2F) has a Research & Development of €0.58 Mil as of Jan. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alzai Health and its competitors.
Is Alzai Health's Research & Development too high?
Alzai Health's current Research & Development is €0.58 Mil. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's Research & Development compare to VRTX and REGN?
Alzai Health's Research & Development of €0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alzai Health and its competitors. Alzai Health's current Research & Development is €0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current Research & Development of €0.58 Mil. The current Research & Development is €0.58 Mil. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current Research & Development is €0.58 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price